BHC: Bausch Health Companies Inc. Stock

by  •  • Comments Off on BHC: Bausch Health Companies Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,098.38
Enterprise Value ($M) 25,479.38
Book Value ($M) -82.00
Book Value / Share -0.22
Price / Book -37.79
NCAV ($M) -21,836.00
NCAV / Share -59.55
Price / NCAV -0.14

Profitability (mra)
Return on Invested Capital (ROIC) -0.03
Return on Assets (ROA) -0.02
Return on Equity (ROE) -4.08

Liquidity (mrq)
Quick Ratio 0.94
Current Ratio 1.30

Balance Sheet (mrq) ($M)
Current Assets 5,596.00
Assets 27,350.00
Liabilities 27,432.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 8,757.00
Operating Income 1,679.00
Net Income -592.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 1,032.00
Cash from Investing -2,145.00
Cash from Financing 1,475.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Goldentree Asset Management Lp 7.80 44.02
02-07 13D/A Icahn Carl C 9.51 1.79

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SE
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSU
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT T
2023-05-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-23 485,683 2,363,870 20.55
2024-04-22 679,782 2,204,234 30.84
2024-04-19 988,013 900,824 109.68
2024-04-18 336,802 713,859 47.18

(click for more detail)

Similar Companies
ADCT – ADC Therapeutics SA ANRO – Alto Neuroscience, Inc.
ANVS – Annovis Bio, Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company


Financial data and stock pages provided by
Fintel.io

Finpedia: Bausch Health